Difficulty: Medium
Average Score: 93%
Practice
A patient who is at risk for osteoporosis will begin taking the selective estrogen receptor modulator raloxifene [Evista]. Which statement will the nurse include when teaching this patient about the medication?
Correct answer
D
Rationale
Raloxifene, a selective estrogen receptor modulator, mimics estrogen├óÔé¼Ôäós bone-protective effects but blocks its action in breast and uterine tissue, reducing breast cancer risk and not increasing endometrial cancer risk. It does, however, increase thromboembolism risk and commonly causes vasomotor symptoms like hot flashes due to its estrogen antagonism in certain tissues. Option D is correct as it highlights a frequent side effect.